Navigation Links
'Move to AMITIZA' Advertising Campaign Underscores the Power of Not Letting Chronic Constipation Slow People Down
Date:11/6/2007

tant administration of food with AMITIZA may reduce symptoms of nausea. Patients who experience severe nausea should inform their physician.

AMITIZA should not be prescribed to patients that have severe diarrhea. Patients should be aware of the possible occurrence of diarrhea during treatment and inform their physician if the diarrhea becomes severe.

In clinical trials, the most common adverse reactions (incidence > 4%) were nausea (29%), diarrhea (12%), headache (11%), abdominal pain (8%), abdominal distention (6%), and flatulence (6%).

For full prescribing information, visit http://www.amitiza.com.

AMITIZA(R) is a registered trademark of Sucampo Pharmaceuticals, Inc.

About Chronic Constipation

Constipation is one of the most common digestive complaints, and is the cause of 2.5 million visits to physicians and 92,000 hospitalizations annually. Constipation is defined as unsatisfactory defecation that is characterized by infrequent stools, difficult stool passage or both. Difficult stool passage includes: straining; hard or lumpy stools; difficulty passing stool; incomplete evacuation; prolonged time to stool; or the need for manual maneuvers to pass stool. Symptoms must persist for at least three consecutive months for the condition to be considered chronic.

Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc., an emerging pharmaceutical company based in Bethesda, Md., focuses on the development and commercialization of drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. The therapeutic potential of prostones was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' chairman and chief executive officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding chief executive officer and advisor, international business development. Sucampo Pha
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc. and Sucampo
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
2. ConforMIS Moves Headquarters to Expanded Facilities in Burlington, MA
3. Mediatech Moves to Prince William County Innovation Park
4. FDA Removes Partial Hold on TELCYTA Clinical Development
5. Emisphere Technologies, Inc. Moves Into New Corporate Headquarters
6. BioSpace and BayBio Launch 11th Edition of Biotech Bay(TM) Hotbed Map Campaign
7. BioSpace, 2008 BIO International Convention and BIOCOM Launch 9th Edition of Biotech Beach Hotbed Map Campaign
8. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
9. Homewatch CareGivers Launches 2007 We Care For Veterans Campaign
10. BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy
11. Nanowire generates power by harvesting energy from the environment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015 A new report ... drugs will reach $22.4bn in 2019. That revenue forecast ... and Market Prospects 2015-2025 ,  published in ... is to provide forecasts and qualitative analyses of the ... and consultancy in London, UK . ...
(Date:4/30/2015)... Spirax Sarco, the leader in product ... announce that for the first time in the company’s ... a Queen’s Award for Innovation – the UK’s highest ... of a unique flowmeter. , The Spirax Sarco ... steam flow measurement. The device provides reliable, accurate ...
(Date:4/30/2015)... 30, 2015 Nitto Avecia, a ... its increased capacity and production capability to serve ... variety and service fulfillment continues to drive Nitto ... process throughput capacities. , In Fall ... downstream process equipment at its Milford, MA facility, ...
(Date:4/30/2015)... SAN DIEGO , April 30, 2015 /PRNewswire/ ... company engaged in the development of biosimilar therapeutics ... today announced the closing of its previously announced ... common stock at a public offering price of ... full by the underwriters of their option to ...
Breaking Biology Technology:Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2
... March 17 VION,PHARMACEUTICALS, INC. (Nasdaq: VIOND ) ... of 2007., The Company reported a net loss ... ended December 31, 2007, compared with a net loss ... common shares,outstanding for the years ended December 31, 2007 ...
... panel for assessment of current risk ... ... Limited (TSX: GEN),a company focused on developing molecular diagnostic tests ... diseases and personalized,health management, today announced that its abstract describing ...
... Axial Biotech, Inc., a company,revolutionizing spine care ... technologies, announced today that it has met several,major ... genetic,prognostic test for Adolescent Idiopathic Scoliosis (AIS) and ... B financing. The Series B financing was,led by ...
Cached Biology Technology:Vion Reports 2007 Fourth Quarter and Year-End Results 2Vion Reports 2007 Fourth Quarter and Year-End Results 3Vion Reports 2007 Fourth Quarter and Year-End Results 4GeneNews selected to present late-breaking abstract at AACR Annual Meeting 2Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing 2
(Date:4/2/2015)... , April 2, 2015 At its 2015 ... Lake City , the American College of Medical ... new directors to its Board.  Members of the ACMG ... and for forming and advancing its policies and programs. ... profession. "It,s an eventful time in medical ...
(Date:4/1/2015)... OXFORD, Conn. , Apr. 1, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... number of Wocket smart wallets is underway to early ... early access group includes usage at retail outlets including ... CVS Pharmacy. Users report Wocket was accepted at all ...
(Date:3/31/2015)... --  Guidepoint , a leading global research services firm, ... TRACKER, part of the Guidepoint TRACKER suite ... device and therapeutics markets. The Post-Surgical Pain Management TRACKER ... share, and adoption rates across three major modalities used ... The Post-Surgical Pain Management TRACKER will provide length ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... Although the two disorders may seem dissimilar, epilepsy and ... to have schizophrenia, and a family history of epilepsy ... known whether the converse is true, i.e., whether a ... epilepsy. Multiple studies using varied investigative techniques ...
... Cracking the Neural Code: Third Annual Aspen Brain Forum ... of Sciences and The Aspen Brain Forum Foundation WHEN: ... www.nyas.org/NeuralCode One of the greatest challenges in neuroscience ... neuronal circuits gives rise to higher order cognition and behavior. ...
... - New research suggests that there could be health ... This antioxidant is a naturally occurring pigment that gives ... certain greens. It also converts to vitamin A, and ... essential nutrient. But scientists at Ohio State University ...
Cached Biology News:Evidence of familial vulnerability for epilepsy and psychosis 2Researchers find potential 'dark side' to diets high in beta-carotene 2Researchers find potential 'dark side' to diets high in beta-carotene 3Researchers find potential 'dark side' to diets high in beta-carotene 4
Request Info...
Immunogen: VDAC3 Protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
... 75 x 25 mm; ... recommended for immunohistochemistry of paraffin-embedded sections, ... end, markings will not ... precleaned, ...
Complete cell culture media with cytokines...
Biology Products: